Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | SLC5A1 | P13866 | 4/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776360 | 0.91 | HTR2C (0.46) | HTR2AHTR2C | |
| SCHEMBL16776371 | 0.88 | BRAF (0.38) | PRMT5WDR77 | |
| SCHEMBL16776361 | 0.84 | BRAF (0.44) | SLC5A1CA2CA9RAF1HTR2A | |
| SCHEMBL16776365 | 0.83 | MPL (0.43) | SLC5A1ARKMOCA2CA9 | |
| SCHEMBL16776347 | 0.80 | ALOX15 (0.38) | SLC5A1 | |
| SCHEMBL16776357 | 0.80 | BRAF (0.40) | SLC5A1KMOCA2CA9 | |
| SCHEMBL16776359 | 0.79 | NPC1 (0.38) | SLC5A1KMOCA2CA9 | |
| SCHEMBL16775914 | 0.79 | CPT2 (0.38) | KMOKDM1A | |
| SCHEMBL1820744 | 0.79 | FGFR4 (0.45) | PHGDHSCN10ACA2CA9DHODH | |
| SCHEMBL16775826 | 0.78 | CA2 (0.40) | SLC5A1KMOCA2CA9RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PHGDH 1138/4885SCN10A 3878/4885SLC5A1 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.